AGC Biologics and Novelty Nobility leaders meet to discuss GMP manufacturing of bispecific drug candidate, NN4101 in Tokyo, Japan on April 13, 2026. From left to right: Seul Eunjin, AGC Biologics; Kunii Shigeru, AGC Biologics; Sung Gong, Novelty Nobility; Park Chan-Hee, Novelty Nobility; Tadashi Murano; AGC Life Sciences Company; Keiko Nakazono, AGC Biologics
AGC Biologics and Novelty Nobility leaders meet to discuss GMP manufacturing of bispecific drug candidate, NN4101 in Tokyo, Japan on April 13, 2026. From left to right: Seul Eunjin, AGC Biologics; Kunii Shigeru, AGC Biologics; Sung Gong, Novelty Nobility; Park Chan-Hee, Novelty Nobility; Tadashi Murano; AGC Life Sciences Company; Keiko Nakazono, AGC Biologics